Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin alfa induction therapy in moderately to severely active ulcerative colitis
jRCT2041220001Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of efavaleukin alfa in autoimmune colitis (4 arms), sponsored by Amgen. Primary endpoint: Clinical remission at Week 12. Started Jan 2022; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2041220001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220001.